Table 1 Characteristics of patients with idiopathic pulmonary fibrosis treated with nintedanib.
Characteristics | Present study | Nintedanib group in INPULSIS (Overall) | Nintedanib group in INPULSIS (Japanese) |
|---|---|---|---|
n = 77 | n = 638 | n = 76 | |
Age | 71.6 ± 8.3 | 66.6 ± 8.1 | 68.4 ± 7.6 |
Sex | |||
Female/Male | 12/65 | 131/507 | 14/62 |
BMI | 22.7 ± 3.95 | 28.1 ± 4.6 | 24.4 ± 3.4 |
Smoking history | |||
No/Yes | 11/66 | 174/464 | 10/66 |
PS | |||
0–1/2–4 | 53/24 | — | — |
mMRC | |||
0–1/2–4 | 36/41 | — | — |
HRCT pattern | |||
Possible UIP/Definite UIP | 24/53 | 213/425 | — |
GAP index | |||
1–5/6–9 | 41/36 | — | — |
Prior treatment (Steroid) | |||
No/Yes | 52/25 | 402/136 | 67/9 |
Initiation dose of nintedanib | |||
300 mg/200 mg | 51/26 | 638/0 | 76/0 |
FVC (mL) | 2.19 ± 0.72 | 2.71 ± 0.76 | 2.42 ± 0.67 |
%FVC (%) | 65.42 ± 19.24 | 79.7 ± 17.6 | 80.9 ± 16.6 |
%DLco (%) | 29.61 ± 12.04 | 47.4 ± 13.5 | 44.6 ± 11.4 |
